DR-430 New transcriptional subgroups of colorectal cancer patients harbouring the BRAF V600E mutation
Colorectal cancer (CRC) remains the second most common cause of cancer death in the world. Approximately 12 % of CRC patients have a mutation in the BRAF gene, which is associated with very aggressive disease. In recent years new drugs for this subpopulation of patients have been developed. Some survival improvements have been reported, however differences in response and duration between patients have been observed. The aim of this project is to better understand the underlying subgroups to improve patient stratification. For this purpose, current gene expression-based classification systems will be refined using the Hartwig Medical dataset and an artificial intelligence approach.
Jose Antonio Seoane Fernandez, Vall d’Hebron Institute of Oncology (VHIO), Spain
Terug naar nieuwsMeer nieuws

Tussenstand GENAYA-project
In april 2022 is Hartwig Medical Foundation gestart met het GENAYA-project. Wat is de stand van zaken? Wat houdt GENAYA …

Structureel verzamelen van data van patiënten kan de zorg voor de patiënten van morgen verbeteren
Op donderdag 25 april 2024, wereld DNA-dag, promoveert Luuk Schipper aan de Universiteit van Utrecht. Zijn promotieonderzoek gaat onder andere …

GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’
The project is an attempt to address the rising healthcare costs associated with new cancer drugs and to identify biomarkers …

Met de complete DNA-test zie je in één keer alle mogelijke doelgerichte kankerbehandelingen. Patiënt en behandelend arts hebben zo alle beschikbare informatie om samen de beslissing over de behandeling te kunnen nemen.